Seattle startup HDT Bio raises $3M to support development of COVID-19 vaccine

Steve Reed, CEO of HDT Bio. (HDT Bio Photo)

Seattle-based biotech company HDT Bio closed a seed round totaling roughly $3 million to support work on its COVID-19 vaccine candidate HDT-301.

Researchers from HDT Bio and the University of Washington in July published a rapid-release paper in the

This post was originally published on this site


Check out